Results 1 to 10 of about 8,322 (134)
Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada [PDF]
BMJ OpenIntroduction Raltegravir is a potent HIV-integrase strand transfer inhibitor (INSTI). Despite its strong activity against HIV-1 strains resistant to other antiretroviral drug classes, it is usually used in combination with other antiretroviral drugs due ...
Salmaan Kanji +6 more
doaj +2 more sources
Raltegravir: first in class HIV integrase inhibitor
Therapeutics and Clinical Risk Management, 2008 Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
exaly +2 more sources
Acta Crystallographica Section E Structure Reports Online, 2013 The hydrated title compound [systematic name:N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-{1-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-ylcarbonyl)amino]ethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide monohydrate], C20H21FN6O5·H2O, is recognised as the first HIV integrase inhibitor.
Yamuna, T. S. +4 more
openaire +4 more sources
Antiviral Therapy, 2022 We report a case of an infant with HIV receiving raltegravir granules for oral suspension and rifampicin-based TB prophylaxis. Raltegravir trough levels remained subtherapeutic and viral load increased during concurrent rifampicin therapy despite using ...
Marlotte AA van der Veer +6 more
doaj +1 more source
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. [PDF]
PLoS ONE, 2009 Raltegravir is an HIV-1 integrase inhibitor currently used in treatment-experienced HIV-1-infected patients resistant to other drug classes. In order to assess its central nervous system penetration, we measured raltegravir concentrations in ...
Aylin Yilmaz +6 more
doaj +1 more source
Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. [PDF]
PLoS ONE, 2014 HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) for HIV infection, has been implicated in HAART-associated cardiovascular complications.
Xiaoxuan Zhang +11 more
doaj +1 more source
Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. [PDF]
PLoS ONE, 2014 The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed.
Jonathan Z Li +30 more
doaj +1 more source
Acta Médica Portuguesa, 2022 Introduction: Although raltegravir has been available since 2007, data are lacking on the Portuguese population living with HIV who initiated this antiretroviral therapy.
Rosário Serrão +15 more
doaj +1 more source
Enfermería Global, 2021 Introducción: El Rategravir pertenece a los inhibidores de integrasas, quedando demostrado y aprobado por diversos ensayos clínicos como un potente antirretroviral seguro y eficaz para el tratamiento de pacientes infectados con el virus de ...
Elias Contreras-Calero +5 more
doaj +1 more source
Raltegravir in treatment naïve patients
European Journal of Medical Research, 2009 Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug resistant viruses.
Cossarini F, Castagna A, Lazzarin A
doaj +1 more source